Resources from the same session
Tumour-agnostic precision therapeutics in molecular oncology: Target versus tissue context: Evidence for benefit and taxonomy considerations
Presenter: Vivek Subbiah
Session: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics
Resources:
Webcast
NGS tissue testing in the search of actionable biomarkers in solid tumours: When is it indicated?
Presenter: Christoph Benedikt Westphalen
Session: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics
Resources:
Webcast
Optimally integrating tumour tissue NGS in the care pathway: Preanalytics, analytics, cost and reimbursement
Presenter: Javier Hernandez-Losa
Session: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics
Resources:
Webcast
The non-small cell lung cancer paradigm in translating NGS information to clear actionable insights: Standardised reporting, molecular tumour boards and decision-support systems
Presenter: Oliver Gautschi
Session: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics
Resources:
Webcast